相关实验视频
Updated: Jun 5, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
GLP-1增强β细胞对摄入蛋白质的反应,而减肥手术会放大β细胞的反应
Maria Rayas1, Samantha Pezzica2, Henri Honka3
1Department of Pediatrics, University of Texas Health at San Antonio, San Antonio, Texas, USA.
Obesity (Silver Spring, Md.)
|December 5, 2024
概括
类似葡萄糖-1 (GLP-1) 在摄入蛋白质期间除了控制葡萄糖之外还有其它作用. 胃绕道 (GB) 或袖子胃切除术 (SG) 等腹腔外科手术可以放大这些GLP-1效应.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 代谢研究研究 代谢研究
背景情况:
- 葡萄糖类-1 (GLP-1) 在摄入蛋白质期间的人类新陈代谢中的作用尚未完全理解.
- 腹腔外科手术,包括胃绕道 (GB) 和袖子胃切除术 (SG),显著改变肠道生理和激素分泌.
研究的目的:
- 研究GLP-1在人类蛋白质摄入过程中的糖分独立作用.
- 确定减肥手术 (GB,SG) 是否改变了GLP-1在摄入蛋白质后对β细胞反应和葡萄糖代谢的贡献.
主要方法:
- 比较胰岛素分泌率 (ISR) 和50克口服蛋白质负载后的葡萄糖流量,在患有GB,SG和对照 (CN) 个体中.
- 使用exendin (Ex-9),GLP-1受体对手,阻止GLP-1的作用在所有组.
- 评估了具有和没有GLP-1受体阻塞的反应.
主要成果:
- 在所有组中,GLP-1受体阻断增加了葡萄糖水平,并降低了β细胞对葡萄糖的敏感性.
- 在对照组中,GLP-1R封锁降低了前食ISR,但在GB和SG组中降低了食用ISR.
- 与对照组相比,GLP-1R阻塞增强了GB和SG患者的胰岛素作用和过度的葡萄糖产生.
结论:
- 在人类摄入蛋白质时,GLP-1 具有胰腺和胰腺外作用.
- 这些GLP-1介导的效应在减肥手术 (GB和SG) 后显著放大.
相关概念视频
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152

